ReviewDiagnostics (Basel, Switzerland)2018
Review of Gallium-68 PSMA PET/CT Imaging in the Management of Prostate Cancer.
Review in Diagnostics (Basel, Switzerland), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 54 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
54 citing papers in PubMed, 3 syntheses or guidelines pooled it, 143 citations in OpenAlex.
- Prostate-specific membrane antigen PET versus [Frontiers in medicine · 2024Pooled it
- Comparison ofFrontiers in oncology · 2024Pooled it
- Radiopharmaceuticals for PET and SPECT Imaging: A Literature Review over the Last Decade.International journal of molecular sciences · 2022Pooled it
- [European journal of nuclear medicine and molecular imaging · 2023Trial
- Exploratory cost-effectiveness analysis ofClinical & experimental metastasis · 2020Trial
- A Prospective Study onJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2019Trial
- Prospective Study of the Radiolabeled GRPR Antagonist BAY86-7548 for Positron Emission Tomography/Computed Tomography Imaging of Newly Diagnosed Prostate Cancer.European urology oncology · 2019Trial
- Early Identification and Management of Biochemical Recurrence Following Radical Prostatectomy.Annals of surgical oncology · 2026Review
- Gallium-Containing Agents for Tumor Diagnosis and Therapy: Current Status and Future Prospects.Small (Weinheim an der Bergstrasse, Germany) · 2026Review
- Easy and versatile preparation ofEJNMMI radiopharmacy and chemistry · 2026Article
- ExpandingEJNMMI radiopharmacy and chemistry · 2026Article
- A tissue-informed deep learning-based method for positron range correction in preclinical [Formula: see text]Ga PET imaging.EJNMMI physics · 2026Article
- Theranostic and Radionuclide-based Treatment Approaches for Radioiodine-refractory Thyroid Cancer: From Biology to Clinical Application.Molecular imaging and biology · 2026Review
- CanInternational urology and nephrology · 2026Article
- RECIP 1.0 more predictive of overall survival than PSMA PET progression criteria in biochemically recurrent prostate cancer.European journal of nuclear medicine and molecular imaging · 2026Article
- Circulating Tumor DNA in Prostate Cancer: A Dual Perspective on Early Detection and Advanced Disease Management.Cancers · 2025Review
- Article
- Evaluating the prognostic value of radiomics and clinical features in metastatic prostate cancer using [Physical and engineering sciences in medicine · 2025Article
- Correlations Between MR Apparent Diffusion Coefficients and PET Standard Uptake Values in Simultaneous MR-PET Imaging of Prostate Cancer.International journal of molecular sciences · 2025Article
- Advances in imaging and artificial intelligence for precision diagnosis and biopsy guidance in prostate cancer.Frontiers in oncology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Over 90% of prostate cancers over-express prostate specific membrane antigen (PSMA) and these tumor cells may be accurately targeted for diagnosis by
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.